Health Care·Pharmaceuticals·$2.8B
Prestige Consumer Healthcare (PBH) operates in the health care sector, focusing on over-the-counter pharmaceuticals. With a market cap of $3 billion, the company plays a crucial role in consumer health, especially as demand for health-related products continues to rise.
EPS
Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profits.
Revenue
Revenue figures will provide insight into the overall sales performance and market demand for Prestige's products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
63%
Avg EPS Surprise
+0.18%
Avg Stock Reaction
+1.87%
In Q3-2026, Prestige reported an EPS of $1.14, slightly below the expected $1.16, resulting in a stock decline of 2.21% the following day. The company continues to navigate a competitive landscape while managing costs.
Management Promises & Guidance
Analysts are cautiously optimistic about Prestige's upcoming earnings, with expectations for a slight rebound in EPS and revenue. The consensus estimates suggest a stable performance compared to previous quarters.
Bull Case
If Prestige can exceed the EPS estimate and show strong revenue growth, it may signal improved market demand and operational efficiency, potentially boosting investor confidence.
Bear Case
Conversely, if the company misses its earnings targets again, it could raise concerns about its ability to compete effectively in the market, leading to further stock declines.
EPS
1.39Earnings per share is a key indicator of profitability and will show how well the company is managing its costs and generating profits.
Revenue
295MRevenue figures will provide insight into the overall sales performance and market demand for Prestige's products.
The print will turn on these two things.
Q1
Will Prestige's EPS exceed the consensus estimate of $1.39?
A beat on EPS could indicate stronger profitability and operational efficiency, which is crucial for investor confidence.
Q2
What revenue figures will Prestige report, and how do they compare to the $295 million consensus?
Revenue performance will provide insights into market demand and the company's competitive position in the health care sector.
Why consensus could be wrong
The consensus may be underestimating the potential for a revenue rebound given recent trends in consumer health spending, which could positively impact Prestige's sales figures.
Supporting Evidence
Recent consumer health trends show increased spending on over-the-counter products, which may not be fully reflected in the consensus estimates.
Options pricing suggests a significant move, indicating that traders expect more volatility than what the consensus reflects.
Key Risk
If revenue comes in below $293 million, it could undermine the bullish sentiment surrounding the stock.
Pre-commit to what would confirm each case.
This quarter's performance is critical as it follows a recent trend of mixed results, and investors are looking for signs of recovery or continued struggles.
Bull Confirmed If
An EPS of $1.40 or higher with revenue exceeding $300 million would confirm the bull case.
Bear Confirmed If
An EPS below $1.38 or revenue falling short of $293 million would confirm the bear case.
Implied Move
±8.98%
Historical Avg
±5.3%
The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.
Options are pricing ±9.0% while PBH has averaged ±5.3% over the last 8 prints — setup is pricing rich.
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options rich in Health Care
n=30Fade rate: 10 of 27 (37%)
This setup has occurred 30 times across Health Care in the last 2 years. 17 of 27 (63%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 6.7%, with a raw directional average of +3.7% (modestly positive historical bias).
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Prestige beats expectations, history suggests a potential stock increase of around 5.17%, confirming a positive outlook.
In-Line / Cautious
If results are in line with expectations, the stock may see muted movement as investors await further guidance.
Miss
A miss could lead to a decline of approximately 3.63%, reflecting ongoing concerns about the company's competitive position.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026